How should I manage a symptomatic bradyarrhythmia, including correction of reversible causes, use of atropine, dopamine or epinephrine, temporary pacing, and indications for permanent pacemaker implantation?

Management of Symptomatic Bradyarrhythmia

For symptomatic bradycardia with hemodynamic compromise, immediately administer atropine 0.5–1 mg IV push and repeat every 3–5 minutes up to a maximum of 3 mg total, while simultaneously preparing transcutaneous pacing pads in case atropine fails. 1, 2

Initial Assessment and Identification

Symptomatic bradycardia is defined as heart rate <50 bpm accompanied by:

• Altered mental status 1, 2
• Systolic blood pressure <80–90 mmHg 2
• Ischemic chest discomfort 1, 2
• Acute heart failure (dyspnea, pulmonary edema) 1, 2
• Signs of shock (cold extremities, poor perfusion) 2
• Syncope or near-syncope 1, 2

Critical distinction: Asymptomatic bradycardia, even with heart rate <40 bpm, requires no treatment and intervention is contraindicated (Class III) as vagal tone may be protective against ventricular fibrillation. 2, 3

First-Line Treatment: Atropine

Dosing Protocol

• Initial dose: 0.5–1 mg IV push immediately 1, 2, 4
• Repeat: Every 3–5 minutes as needed 1, 2, 4
• Maximum total dose: 3 mg (or 2–3 mg in post-MI patients) 1, 2, 4
• Critical warning: Doses <0.5 mg may paradoxically worsen bradycardia via parasympathomimetic effect and must be avoided 1, 2, 4

Expected Efficacy Based on Block Level

Atropine is likely effective (Class I) for:

• Sinus bradycardia 1, 2, 4
• First-degree AV block 2
• Mobitz I (Wenckebach) second-degree AV block 1, 2, 4
• Vagally mediated bradycardia (e.g., inferior MI, airway manipulation) 2, 4

Atropine is ineffective or contraindicated (Class III) for:

• Mobitz II second-degree AV block with wide QRS 1, 2, 4
• Third-degree AV block with wide QRS complex 1, 2, 4
• Anterior MI with new bundle branch block 2
• Heart transplant patients without autonomic reinnervation (may cause paradoxical high-grade AV block—use epinephrine instead) 1, 2

Special Considerations in Acute Coronary Syndrome

• Limit total atropine dose to 2–3 mg in post-MI patients 2
• Target heart rate ≈60 bpm only—avoid aggressive rate increases that worsen ischemia or enlarge infarct size 2
• Atropine is most effective for inferior MI-related bradycardia within the first 6 hours 2

Second-Line Treatment: When Atropine Fails

Transcutaneous Pacing (TCP)

Initiate TCP immediately in unstable patients who do not respond to atropine—do not delay pacing while giving additional atropine doses (Class IIa). 1, 2, 3

• Apply pacing pads prophylactically in high-risk patients before the first atropine dose 2
• TCP serves as a bridge to transvenous or permanent pacing 1, 2
• Sedation/analgesia may be required due to pain in conscious patients 2

Chronotropic Infusions (Class IIb)

If atropine and TCP fail or pacing is unavailable:

Agent	Initial Dose	Titration	Maximum Dose	Preferred Scenario
Dopamine	5–10 µg/kg/min IV	Increase by 2–5 µg/kg/min every 2 min	20 µg/kg/min	Most bradyarrhythmias; provides chronotropic + inotropic support [1,2]
Epinephrine	2–10 µg/min IV (or 0.1–0.5 µg/kg/min)	Titrate to HR/BP response	No fixed cap	Severe hypotension requiring combined chronotropic/inotropic/vasopressor effects; heart transplant patients [1,2]
Isoproterenol	20–60 µg IV bolus or 1–20 µg/min infusion	Titrate to HR response	—	Ischemic cardiomyopathy (pure β-agonist without vasoconstriction) [2]

Critical warnings:

• Dopamine >20 µg/kg/min causes excessive vasoconstriction and arrhythmias without additional heart rate benefit 1, 2
• All chronotropic agents increase myocardial oxygen demand and may worsen ischemia in acute coronary syndromes 1, 2
• Use with extreme caution in coronary ischemia; limit heart rate increase to ≈60 bpm 2

Correction of Reversible Causes

Before proceeding to permanent pacing, identify and treat reversible etiologies (Class I): 1

• Drug toxicity: Taper/discontinue β-blockers, calcium channel blockers (diltiazem, verapamil), digoxin, amiodarone, quetiapine 1, 2
• Metabolic: Correct hyperkalemia, hypothyroidism 1
• Infectious: Treat Lyme carditis with medical therapy and temporary pacing if necessary 1
• Inflammatory: Cardiac sarcoidosis may warrant permanent pacing with defibrillator capability without waiting for reversibility (Class IIa) 1

Exception: In patients on chronic, medically necessary antiarrhythmic or β-blocker therapy who develop symptomatic second- or third-degree AV block, proceeding directly to permanent pacing without drug washout is reasonable (Class IIa). 1

Indications for Permanent Pacemaker (Class I)

Permanent pacemaker implantation is indicated when symptomatic bradycardia persists after excluding reversible causes: 1, 2

• Documented sinus node dysfunction with symptomatic bradycardia 1
• Symptomatic sinus bradycardia caused by guideline-directed medical therapy when no alternative treatment exists 1
• High-grade AV block (Mobitz II or third-degree) with symptoms 1
• Bifascicular block with intermittent complete heart block and symptoms 2
• Tachy-brady syndrome with symptoms attributable to bradycardia (Class IIa) 1

Pacing Mode Selection

• Atrial-based pacing (AAI or DDD) is preferred over single-chamber ventricular pacing in symptomatic sinus node dysfunction with intact AV conduction (Class I) 1
• Dual-chamber devices should be programmed to minimize ventricular pacing when AV conduction is preserved 1
• Rate-responsive programming is reasonable for chronotropic incompetence (Class IIa) 1

Special Clinical Scenarios

Neurogenic Shock (Spinal Cord Injury)

• Bradycardia is often refractory to atropine due to unopposed parasympathetic activity 2
• Consider aminophylline 6 mg/kg IV over 20–30 minutes or dopamine 5–20 µg/kg/min 2

Drug-Induced Bradycardia in Parkinson's Disease

• Quetiapine should be tapered and discontinued first as the most reversible cause 2
• Review and reduce/discontinue β-blockers, non-dihydropyridine calcium channel blockers, digoxin, amiodarone 2
• Monitor heart rate and blood pressure weekly for the first month, then monthly 2

Post-Myocardial Infarction with Sedation

• Reduce or stop remifentanil infusion by ≥50% (ultra-short half-life 3–10 min) 2
• Switch to fentanyl (25–100 µg bolus, 25–300 µg/h infusion) which has milder bradycardic profile 2
• Limit atropine to 2–3 mg total and target HR ≈60 bpm only 2

Critical Pitfalls to Avoid

• Do not treat asymptomatic bradycardia even if HR <40 bpm (Class III—may be protective) 2, 3
• Do not delay transcutaneous pacing in unstable patients while giving multiple atropine doses 1, 2
• Do not exceed atropine 3 mg total (or 2–3 mg in post-MI) to avoid tachycardia and anticholinergic toxicity 1, 2
• Do not use atropine for infranodal blocks (Mobitz II or third-degree with wide QRS)—it will not improve conduction and may worsen the block 1, 2, 4
• Do not exceed dopamine 20 µg/kg/min—higher doses cause vasoconstriction and arrhythmias without benefit 1, 2
• Do not start dopamine before attempting atropine—atropine is safer and more appropriate first-line 2